InflaRx N.V.
IFRXHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company carries a $297.5M market cap, placing it firmly in the micro-cap category. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Market Cap
$297.5M
Beta
2.46
P/E (TTM)
—
P/E (Fwd)
-4.73
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.43
ROE
-79.9%
ROA
-39.1%
Cash
$39.8M
Total Debt
$823,028
Free CF
-$15.9M
52W Change
137.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $39.8M in cash comfortably exceeding the $823K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$15.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -79.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.46 means IFRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for InflaRx N.V. and its sector.